Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer

Journal of Immunology

Volumn 191, Issue 6, 2013, Pages 3232-3239

  Bendle, Gavin M ^a,b   Linnemann, Carsten ^a   Bies, Laura ^a   Song, Ji Ying ^a   Schumacher, Ton N M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; FLOW CYTOMETRY; GENETIC ENGINEERING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; TISSUE DIFFERENTIATION; TUMOR REGRESSION; WHOLE BODY RADIATION;

ANIMALS; FLOW CYTOMETRY; GENETIC THERAPY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84884230890     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301270     Document Type: Article

References (62)

1. Horowitz, M. M., R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H. J. Kolb, A. A. Rimm, O. Ringdén, C. Rozman, B. Speck, et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562.
2. Kolb, H. J., J. Mittermüller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. Heim, and W. Wilmanns. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462-2465.
3. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2: 957-961.
4. de Witte, M. A., M. Coccoris, M. C. Wolkers, M. D. van den Boom, E. M. Mesman, J. Y. Song, M. van der Valk, J. B. Haanen, and T. N. Schumacher. 2006. Targeting self-antigens through allogeneic TCR gene transfer. Blood 108: 870-877.
5. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
6. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
7. Robbins, P. F., R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, A. V. Nahvi, L. J. Helman, C. L. Mackall, et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29: 917-924.
8. Kvistborg, P., C. J. Shu, B. Heemskerk, M. Fankhauser, C. A. k. Thrue, M. Toebes, N. van Rooij, C. Linnemann, M. van Buuren, J. H. M. Urbanus, et al. 2012. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients. Oncoimmunology 1: 409-418.
9. Dash, P., J. L. McClaren, T. H. Oguin, III, W. Rothwell, B. Todd, M. Y. Morris, J. Becksfort, C. Reynolds, S. A. Brown, P. C. Doherty, and P. G. Thomas. 2011. Paired analysis of TCRa and TCRb chains at the single-cell level in mice. J. Clin. Invest. 121: 288-295.
10. Sadovnikova, E., and H. J. Stauss. 1996. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 93: 13114-13118.
11. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, et al. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2: 962-970.
12. Wilde, S., D. Sommermeyer, B. Frankenberger, M. Schiemann, S. Milosevic, S. Spranger, H. Pohla, W. Uckert, D. H. Busch, and D. J. Schendel. 2009. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 114: 2131-2139.
13. Li, L. P., J. C. Lampert, X. Chen, C. Leitao, J. Popović, W. Mü ller, and T. Blankenstein. 2010. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat. Med. 16: 1029-1034.
14. Li, Y., R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, and J. M. Boulter. 2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23: 349-354.
15. Jorritsma, A., R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. Schumacher, and J. B. Haanen. 2007. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110: 3564-3572.
16. Kuball, J., M. L. Dossett, M. Wolfl, W. Y. Ho, R. H. Voss, C. Fowler, and P. D. Greenberg. 2007. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109: 2331-2338.
17. Cohen, C. J., Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66: 8878-8886.
18. Cohen, C. J., Y. F. Li, M. El-Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan. 2007. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67: 3898-3903.
19. Bendle, G. M., C. Linnemann, A. I. Hooijkaas, L. Bies, M. A. de Witte, A. Jorritsma, A. D. Kaiser, N. Pouw, R. Debets, E. Kieback, et al. 2010. Lethal graft-versushost disease in mouse models of T cell receptor gene therapy. Nat. Med. 16: 565-570, 1p following 570.
20. Provasi, E., P. Genovese, A. Lombardo, Z. Magnani, P. Q. Liu, A. Reik, V. Chu, D. E. Paschon, L. Zhang, J. Kuball, et al. 2012. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18: 807-815.
21. Rubtsov, Y. P., and A. Y. Rudensky. 2007. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat. Rev. Immunol. 7: 443-453.
22. Li, M. O., and R. A. Flavell. 2008. TGF-beta: a master of all T cell trades. Cell 134: 392-404.
23. Zhang, N., and M. J. Bevan. 2012. TGF-b signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat. Immunol. 13: 667-673.
24. Bollard, C. M., C. Rössig, M. J. Calonge, M. H. Huls, H. J.Wagner, J. Massague, M. K. Brenner, H. E. Heslop, and C. M. Rooney. 2002. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99: 3179-3187.
25. Wrzesinski, S. H., Y. Y. Wan, and R. A. Flavell. 2007. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13: 5262-5270.
26. Dong, M., and G. C. Blobe. 2006. Role of transforming growth factor-beta in hematologic malignancies. Blood 107: 4589-4596.
27. Wikström, P., P. Stattin, I. Franck-Lissbrant, J. E. Damber, and A. Bergh. 1998. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37: 19-29.
28. Torre-Amione, G., R. D. Beauchamp, H. Koeppen, B. H. Park, H. Schreiber, H. L. Moses, and D. A. Rowley. 1990. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87: 1486-1490.
29. Tamada, K., M. Harada, K. Abe, T. Li, H. Tada, Y. Onoe, and K. Nomoto. 1997. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes. J. Immunol. 158: 4846-4854.
30. Seo, N., Y. Tokura, M. Takigawa, and K. Egawa. 1999. Depletion of IL-10-and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163: 242-249.
31. Willimsky, G., and T. Blankenstein. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437: 141-146.
32. Gorelik, L., and R. A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7: 1118-1122.
33. Zhang, L., Z. Yu, P. Muranski, D. C. Palmer, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2013. Inhibition of TGF-b signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 20: 575-580.
34. Quatromoni, J. G., Y. Wang, D. D. Vo, L. F. Morris, A. R. Jazirehi, W. McBride, T. Chatila, R. C. Koya, and J. S. Economou. 2012. T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFb) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J. Transl. Med. 10: 127.
35. Donkor, M. K., A. Sarkar, P. A. Savage, R. A. Franklin, L. K. Johnson, A. A. Jungbluth, J. P. Allison, and M. O. Li. 2011. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-b1 cytokine. Immunity 35: 123-134.
36. Chou, C. K., A. Schietinger, H. D. Liggitt, X. Tan, S. Funk, G. J. Freeman, T. L. Ratliff, N. M. Greenberg, and P. D. Greenberg. 2012. Cell-intrinsic abrogation of TGF-b signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J. Immunol. 189: 3936-3946.
37. Greenberg, N. M., F. DeMayo, M. J. Finegold, D. Medina, W. D. Tilley, J. O. Aspinall, G. R. Cunha, A. A. Donjacour, R. J. Matusik, and J. M. Rosen. 1995. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92: 3439-3443.
38. Kessels, H. W., K. Schepers, M. D. van den Boom, D. J. Topham, and T. N. Schumacher. 2006. Generation of T cell help through a MHC class Irestricted TCR. J. Immunol. 177: 976-982.
39. Shappell, S. B., G. V. Thomas, R. L. Roberts, R. Herbert, M. M. Ittmann, M. A. Rubin, P. A. Humphrey, J. P. Sundberg, N. Rozengurt, R. Barrios, et al. 2004. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 64: 2270-2305.
40. Johnson, M. A., I. Hernandez, Y. Wei, and N. Greenberg. 2000. Isolation and characterization of mouse probasin: an androgen-regulated protein specifically expressed in the differentiated prostate. Prostate 43: 255-262.
41. Gray, A., M. de la Luz Garcia-Hernandez, M. van West, S. Kanodia, B. Hubby, and W. M. Kast. 2009. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 27(Suppl. 6): G52-G59.
42. Watkins, S. K., Z. Zhu, E. Riboldi, K. A. Shafer-Weaver, K. E. Stagliano, M. M. Sklavos, S. Ambs, H. Yagita, and A. A. Hurwitz. 2011. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121: 1361-1372.
43. de Witte, M. A., G. M. Bendle, M. D. van den Boom, M. Coccoris, T. D. Schell, S. S. Tevethia, H. van Tinteren, E. M. Mesman, J. Y. Song, and T. N. Schumacher. 2008. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J. Immunol. 181: 2563-2571.
44. Degl'Innocenti, E., M. Grioni, A. Boni, A. Camporeale, M. T. Bertilaccio, M. Freschi, A. Monno, C. Arcelloni, N. M. Greenberg, and M. Bellone. 2005. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 35: 66-75.
45. Goldstein, A. S., D. A. Lawson, D. Cheng, W. Sun, I. P. Garraway, and O. N. Witte. 2008. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl. Acad. Sci. USA 105: 20882-20887.
46. Wang, X., M. Kruithof-de Julio, K. D. Economides, D. Walker, H. Yu, M. V. Halili, Y. P. Hu, S. M. Price, C. Abate-Shen, and M. M. Shen. 2009. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500.
47. Leong, K. G., B. E. Wang, L. Johnson, and W. Q. Gao. 2008. Generation of a prostate from a single adult stem cell. Nature 456: 804-808.
48. Wrzesinski, C., C. M. Paulos, L. Gattinoni, D. C. Palmer, A. Kaiser, Z. Yu, S. A. Rosenberg, and N. P. Restifo. 2007. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117: 492-501.
49. Paulos, C. M., C. Wrzesinski, A. Kaiser, C. S. Hinrichs, M. Chieppa, L. Cassard, D. C. Palmer, A. Boni, P. Muranski, Z. Yu, et al. 2007. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117: 2197-2204.
50. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912.
51. Lizée, G., L. G. Radvanyi, W. W. Overwijk, and P. Hwu. 2006. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin. Cancer Res. 12: 2359s-2365s.
52. Busse, A., and U. Keilholz. 2011. Role of TGF-b in melanoma. Curr. Pharm. Biotechnol. 12: 2165-2175.
53. Flavell, R. A., S. Sanjabi, S. H. Wrzesinski, and P. Licona-Limón. 2010. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10: 554-567.
54. Ishigame, H., M. M. Mosaheb, S. Sanjabi, and R. A. Flavell. 2013. Truncated form of TGF-bRII, but not its absence, induces memory CD8+ T cell expansion and lymphoproliferative disorder in mice. J. Immunol. 190: 6340-6350.
55. Lucas, P. J., S. J. Kim, S. J. Melby, and R. E. Gress. 2000. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J. Exp. Med. 191: 1187-1196.
56. Zhang, W., M. Tsuda, G. X. Yang, K. Tsuneyama, X. S. He, A. A. Ansari, W. M. Ridgway, R. L. Coppel, Z. X. Lian, P. S. Leung, and M. E. Gershwin. 2012. Lymphoma-like T cell infiltration in liver is associated with increased copy number of dominant negative form of TGFb receptor II. PLoS One 7: e49413.
57. Zhang, L., S. P. Kerkar, Z. Yu, Z. Zheng, S. Yang, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2011. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19: 751-759.
58. Chmielewski, M., C. Kopecky, A. A. Hombach, and H. Abken. 2011. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71: 5697-5706.
59. Borkner, L., A. Kaiser, W. van de Kasteele, R. Andreesen, A. Mackensen, J. B. Haanen, T. N. Schumacher, and C. Blank. 2010. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol. Immunother. 59: 1173-1183.
60. Krieg, C., S. Létourneau, G. Pantaleo, and O. Boyman. 2010. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl. Acad. Sci. USA 107: 11906-11911.
61. Kerkar, S. P., P. Muranski, A. Kaiser, A. Boni, L. Sanchez-Perez, Z. Yu, D. C. Palmer, R. N. Reger, Z. A. Borman, L. Zhang, et al. 2010. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70: 6725-6734.
62. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.